Cytek Biosciences Announces Share Repurchase Program

On December 30th, 2025, Cytek Biosciences (NASDAQ:CTKB) declared that its board of directors has approved a new share repurchase program. The program allows the company to buy back up to $50 million worth of its outstanding shares, representing around 5.9% of its current stock. This decision is often seen as a signal from the board that they believe the company's stock is currently undervalued.

Analyst Insights

In recent analyst reports, Piper Sandler revisited their price target for Cytek Biosciences, increasing it from $8.00 to $8.50. They have also assigned an "overweight" rating to the stock, indicating a positive outlook.

Cytek Biosciences Stock Overview

As of Wednesday, Cytek Biosciences shares opened at $6.49. The company holds a market capitalization of approximately $835.98 million, with a price-to-earnings ratio of -81.11. Cytek's stock has shown a fifty-day moving average price of $6.21 and a two-hundred day moving average of $5.80. Over the past year, the stock hit a low of $4.66 and a high of $9.33.

Most recently, Cytek Biosciences reported its quarterly earnings on November 5th, where they posted earnings of $0.01 per share. This result surpassed analysts' expectations, who projected a loss of $0.02 per share. In terms of revenue, the company garnered $51.5 million during this quarter, slightly above the anticipated $50.63 million. However, the company reported a negative return on equity of 2.58% with a net margin of -5.05%. Analysts estimate a loss of $0.06 per share for the current fiscal year.

About Cytek Biosciences

Cytek Biosciences, Inc. specializes in providing cell analysis solutions that support advancements in biomedical research and clinical applications. Their product lineup includes various systems designed for cell analysis, such as aurora and northern lights systems that utilize multi-laser fluorescence signatures, and the aurora cell sorter system that enhances application diversity across cell analysis methods.

Additional Information

• Exploring alternatives: Five stocks we like better than Cytek Biosciences
• Learn about fixed income: CD Calculator
• Health tech insights: 3 Stocks Helping to Bring AI to Healthcare
• Construction sector prospects: Investing in Construction Stocks
• New year outlooks: 3 Stocks Ringing in The New Year With Large Buyback Announcements
• Tech trends: 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
• Market reflections: Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better

Stay informed about Cytek Biosciences - Subscribe for daily updates on the latest news and ratings related to Cytek Biosciences and similar companies.

Repurchase, Stocks, Earnings